ASX:ENP

4 stories mentioning ASX:ENPUpdated 27d ago

Every FINWIRES story that references ASX:ENP, newest first.

Entropy Neurodynamics Completes First-Cohort Dosing in Binge Eating Disorder Trial

Entropy Neurodynamics (ASX:ENP) said it completed dosing for all six participants in the first cohort of its phase two clinical trial of TRP-8803 for the treatment of patients with binge eating disorder, according to a Tuesday filing with the Australian bourse.Each participant received two doses of TRP-8803 delivered 14 days apart alongside supportive therapy, per the filing.Participants in the first cohort received a mid-range therapeutic dose, and the regimen for the second cohort will be decided after a review of outcomes for the first cohort."Importantly, dosing in cohort one achieved a controlled and reproducible psychedelic response across all participants," Entropy Neurodynamics said.

ASX:ENP

Asia38d ago

Entropy Neurodynamics Says Various Securities Due for Escrow Release; Shares Up 3%

Entropy Neurodynamics (ASX:ENP) said a range of its restricted securities will be released from escrow on May 29, following which it will not have any securities remaining in escrow, according to a Friday filing with the Australian bourse.The securities to be released include about 49.9 million ordinary shares, as well as various options, per the filing.The company said it will apply to quote the ordinary shares within five business days after the end of the escrow period.Shares of Entropy Neurodynamics gained nearly 3% in recent Friday trade.

ASX:ENP

Asia55d ago

Entropy Neurodynamics Files US Patent Application After Clinical Insights From Phase 2A IBS Study, Shares Down 5%

Entropy Neurodynamics (ASX:ENP) filed a US provisional patent application based on clinical insights from the results of its phase 2a study of TRP-8802, or oral psilocybin, in patients with treatment-resistant, irritable bowel syndrome (IBS), according to a Tuesday Australian bourse filing.The filing is in addition to its existing international patent application related to psychedelic-assisted therapy for disorders of gut-brain interaction, which was filed under the Patent Cooperation Treaty on Jan. 3, 2024.The results highlighted a 75% response rate in treatment-resistant IBS patients, which the firm noted was the strongest clinical signal ever reported in IBS drug development.Its shares fell 5% in recent trading on Tuesday.

ASX:ENP

Asia56d ago

Entropy Neurodynamics Says Irritable Bowel Syndrome Drug Candidate Showed 75% Response Rate in Phase 2a Study; Shares Gain 3%

Entropy Neurodynamics (ASX:ENP) said its TRP-8802 drug candidate showed a 75% response rate in a phase 2a clinical study for the treatment of irritable bowel syndrome, according to a Monday filing with the Australian bourse.The results mark the "strongest clinical signal ever reported" in irritable bowel syndrome drug development and represent a treatment breakthrough compared with current therapies that register response rates of 17% to 44%, the company said.The study analyzed two doses of TRP-8802 oral psilocybin alongside structured psychotherapy in 12 patients who had earlier failed multiple standard treatments, with the data indicating that the therapy candidate is targeting root-cause neurobiological pathways instead of just masking the chronic disorder's symptoms, Entropy said.TRP-8802's safety profile was consistent with expectations for psychedelic‑assisted therapy, and the one serious adverse event that was recorded was resolved with clinical support, per the filing.The company said it is in a strong position for partnering negotiations, larger trials, and grant funding opportunities, with a clear development pathway focused on the US, where patients spend more than $60 billion per year on treatments for the disease.Entropy Neurodynamics shares gained 3% in recent Monday trade.

ASX:ENP

Track with the FINWIRES app suite

FolioX

Track ASX:ENP in your portfolio

WheelAI

Analyze ASX:ENP options with the wheel strategy

StockInsider

See market sentiment on ASX:ENP